Evaluation

3

Review clinical trials related to Evaluation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Hospitalizations

The aim of this study is to develop, study and validate a rigorous and sustainable method for assessing the clinical appropriateness of the decision taken in the Emergency Department to admit or not to admit patients.

Participants needed: 240,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Mario Negri Institute for Pharmacological ResearchUpdated: May 19, 2026Locations: 7
Eligibility criteria

Not listed

Status: Recruiting

Health-care Quality in Semi-intensive Care Units

The main aim of this study is to realize a system of continuous evaluation of healthcare quality in semi-intensive care units.

Participants needed: 39,000
Trial details
Biological sex: AllType: ObservationalSponsor: Mario Negri Institute for Pharmacological ResearchUpdated: May 20, 2026Locations: 18
Eligibility criteria

all patients hospitalised in a semi-intensive care unit

None

Status: Recruiting

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

Investigators established the efficacy evaluation criteria for tumor markers (RecistTM) in the preliminary research. Among patients with advanced non-small cell lung cancer, patients with positive driving genes are more likely to exhibit abnormalities in tumor markers, which suggests that this criteria may be more suitable for evaluating the efficacy of targeted therapy in driving gene positive patients. Moreover, The judgment rules of the prelimary criteria still need further improvement. Therefore, in order to broaden the application scope of the RecistTM criteria, further improve the evaluation rules of RecistTM criteria, and multi-dimensionally confirm the reliability of RecistTM criteria on efficacy evaluation, investigators plan to conduct research on the application of RecistTM criteria in evaluating the efficacy of targeted therapy for advanced non-small cell lung cancer with positive driving genes.

Participants needed: 44
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Xueqin YangUpdated: Nov 21, 2023Locations: 1
Eligibility criteria

NSCLC patients with stage IIIB-IV [+8]

Patients with dysphagia; [+2]